Designer babies crawl closer
By Laurie Zoloth,
Cosmos Magazine
| 10. 05. 2015
Untitled Document
Super crops and healthy productive farm animals; mosquito populations controlled without pesticides; a cure for cancer … This fantasy world has loomed since the 1970s when we first learnt how to edit DNA, the code of life.
But the technology to do so turned out to be cumbersome, costly and unreliable. The failure rate in animal tests was so high that fixing a person’s genetic disease became out of the question.
This began to change with the discovery of proteins purpose-built to modify DNA: so-called zinc finger nuclei in the 1990s and TALENS in 2009. The success rate climbed high enough to start clinical trials: zinc finger nuclei were used to make human immune cells resistant to HIV, and TALENS was used to repair the gene that causes Severe Combined Immunodeficiency (SCID).
And then scientists uncovered a new DNA-editing strategy in bacteria, used to edit out invading viruses. It was a modular system composed of proteins and RNA, termed CRISPR. And like all modular systems, it offered amazing versatility. The protein module (CAS 9) was a missile that...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...